Eli Lilly Expands Weight Loss Drug Access to Low- and Middle-Income Countries
Eli Lilly has launched the 'Lilly Change the Course Commitment,' aiming to treat as many patients with diabetes and obesity in low- and middle-income countries (LMICs) by 2040 as it does in wealthier nations. This initiative targets a massive global market, where over two billion people are overweight or obese and nearly one billion have diabetes. The company plans to collaborate with local health systems and organizations to improve access to its weight-loss drugs like Zepbound and Foundayo. Eli Lilly's strategy could significantly expand its addressable patient base by leveraging the large population in LMICs, despite lower revenue per patient compared to wealthier countries. Its oral drug Foundayo may offer manufacturing advantages over injectables such as Zepbound, potentially enabling broader distribution at reduced costs. The initiative also aims to strengthen healthcare infrastructure and build long-term relationships that could give Eli Lilly a competitive edge. This move aligns with the company's growth in the obesity market amid rising global demand for weight-loss treatments.
Tickers: $LLY
Topics: Eli Lilly LMIC access obesity market weight-loss drugs